title: Comparison of insulin detemir and insulin glargine on glycemic variability in patients with type 1 and type 2 diabetes.
abstract: OBJECTIVE
  To compare the glycemic variability of insulin detemir and insulin glargine in type 1 and type 2 diabetic patients.
  
  
  METHODS
  15 type 1 and 14 type 2 diabetic patients receiving intensive insulin therapy with insulin glargine were enrolled. Before and after switching insulin glargine to insulin detemir, we assessed fasting glucose variability using the standard deviation (SD) and the coefficient of variance (CV) of self-monitored fasting blood sugar (FBS) levels.
  
  
  RESULTS
  The SD and CV values were significantly decreased in type 1 diabetes after switching the therapy, though there was no significant difference in type 2 diabetes. The frequency of hypoglycemia was decreased in type 1 diabetes and there was no change in type 2 diabetes. The changes of the CV value also showed significant positive correlation with fasting serum CPR levels in all patients and total insulin dose in type 1 diabetes. The changes of frequency of hypoglycemia showed significant positive correlation with total and basal insulin dose adjusted for body weight in type 1 diabetes.
  
  
  CONCLUSIONS
  The present study demonstrated lower within-subject variability of insulin detemir compared to insulin glargine, suggesting that the basal insulin replacement with insulin detemir may provide a useful therapeutic strategy for uncontrolled type 1 diabetes with high glucose variability.
authors.affiliation: Department of Diabetes and Metabolism, National Hospital Organization Okayama Medical Center, Okayama, Japan. aitone@okayama3.hosp.go.jp
authors.forename: A
authors.initials: A
authors.lastname: Tone
authors.forename: I
authors.initials: I
authors.lastname: Iseda
authors.forename: C
authors.initials: C
authors.lastname: Higuchi
authors.forename: K
authors.initials: K
authors.lastname: Tsukamoto
authors.forename: A
authors.initials: A
authors.lastname: Katayama
authors.forename: Y
authors.initials: Y
authors.lastname: Matsushita
authors.forename: K
authors.initials: K
authors.lastname: Hida
authors.forename: J
authors.initials: J
authors.lastname: Wada
authors.forename: K
authors.initials: K
authors.lastname: Shikata
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D001794:Blood Pressure; D002096:C-Peptide / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005215:Fasting; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000069057:Insulin Detemir; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D061389:Insulin, Regular, Pork; D008297:Male; D008875:Middle Aged; D015203:Reproducibility of Results
chemical_list: D001786:Blood Glucose; D002096:C-Peptide; D002097:C-Reactive Protein; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D000069057:Insulin Detemir; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D061389:Insulin, Regular, Pork; C000006:insulin, neutral